Displaying One Session

Mirati Therapeutics, Inc. - Advancing Tailored Therapies in NSCLC and KRASG12C-Driven Tumors (ID 85)

Time
10:15 - 11:45

Welcome and Introduction (ID 5846)

Unmet Needs and Recent Advances for NSCLC (ID 5847)

Emerging Therapies to Overcome CPI Resistance in NSCLC (ID 5848)

New Perspectives with Targeted Options for KRAS -Driven Tumors (ID 5849)

Q&A (ID 5850)

Summary & Close (ID 5851)